
    
      The broad objective of this protocol is to advance our understanding of the
      pathophysiological mechanisms of human Cardiorenal Syndrome (CRS) with a specific emphasis
      upon the biological interaction between diuretic therapy, the
      renin-angiotensin-aldosterone-system (RAAS) and cyclic 3'-5'-guanosine monophosphate (cGMP)
      pathway.
    
  